Urethral Neoplasms: Clinical Trials

7 trials for Urethral Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Completed 7
Phase 21Completed 1

Follow Urethral Neoplasms: new trials by email Literature Review of Urethral Neoplasms trials Research Report on Urethral Neoplasms

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Ramucirumab, Docetaxel, Placebo - Urothelial Carcinoma
Phase 3CompletedEli Lilly and Company5302015-07-132023-08-21
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Bevacizumab, Cisplatin, Gemcitabine Hydrochloride - Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma
Phase 3CompletedNational Cancer Institute (NCI)5062009-07-152026-06-24
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Fentanyl sublingual spray, Placebo - Cancer
Phase 3CompletedINSYS Therapeutics Inc1302007-10-012014-03-05
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
cisplatin, gemcitabine hydrochloride, paclitaxel - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC6082001-05-012013-06-12
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
carboplatin, gemcitabine hydrochloride, methotrexate - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Phase 2 / Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC2382001-01-012013-06-12
Combination Chemotherapy in Treating Patients With Bladder Cancer
carboplatin, cisplatin, doxorubicin hydrochloride - Bladder Cancer, Urethral Cancer
Phase 3CompletedEastern Cooperative Oncology Group4901999-04-022023-06-15
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
carboplatin, cisplatin, doxorubicin hydrochloride - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Phase 3CompletedEastern Cooperative Oncology Group3301998-12-032023-06-22

Narrower conditions

Urinary Bladder Neoplasms (6)  ·  Carcinoma, Transitional Cell (2)  ·  Prostatic Neoplasms (2)  ·  Adrenocortical Carcinoma (1)  ·  Anus Neoplasms (1)  ·  Appendiceal Neoplasms (1)  ·  Astrocytoma (1)  ·  Bile Duct Neoplasms (1)  ·  Blast Crisis (1)  ·  Brain Neoplasms (1)  ·  Breast Carcinoma In Situ (1)  ·  Breast Neoplasms (1)  ·  Breast Neoplasms, Male (1)  ·  Burkitt Lymphoma (1)

Broader conditions

Female Urogenital Diseases (7)  ·  Female Urogenital Diseases and Pregnancy Complications (7)  ·  Male Urogenital Diseases (7)  ·  Neoplasms by Site (7)  ·  Urethral Diseases (7)  ·  Urogenital Diseases (7)  ·  Urogenital Neoplasms (7)  ·  Urologic Diseases (7)  ·  Urologic Neoplasms (7)  ·  Neoplasms (6)  ·  Urinary Bladder Diseases (6)  ·  Carcinoma (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Genital Diseases (2)

Interventions

Cisplatin (4)  ·  Carboplatin (3)  ·  Gemcitabine (3)  ·  Methotrexate (3)  ·  Paclitaxel (3)  ·  Vinblastine (3)  ·  Doxorubicin (2)  ·  1,2-diaminocyclohexaneplatinum II citrate (1)  ·  Bevacizumab (1)  ·  Disulfides (1)  ·  Docetaxel (1)  ·  Fentanyl (1)  ·  Immunoglobulin G (1)  ·  Platinum (1)  ·  Ramucirumab (1)

Sponsors

Eastern Cooperative Oncology Group (2)  ·  European Organisation for Research and Treatment of Cancer - EORTC (2)  ·  Eli Lilly and Company (1)  ·  INSYS Therapeutics Inc (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (6)  ·  Belgium (3)  ·  Denmark (3)  ·  Germany (3)  ·  Hungary (3)  ·  Israel (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Poland (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Austria (2)  ·  Canada (2)  ·  France (2)

Top investigators

Bruce J. Roth, MD (2)  ·  Andreas Boehle, MD (1)  ·  Christoph Zielinski, MD (1)  ·  David C. Smith, MD (1)  ·  Gerwin Kaiser, MD (1)  ·  Joaquim Bellmunt, MD, PhD (1)  ·  Jonathan E Rosenberg (1)  ·  Jose Baselga, MD (1)  ·  Larry Dillaha, MD (1)  ·  Malcolm J. Moore, MD (1)  ·  Martin J. Edelman, MD (1)  ·  Michael Leahy, MBChB, FRACP, FRCP, FRC Path (1)  ·  Stephane Culine, MD (1)

Results publications

PMID 15073851, PMID 19786668, PMID 22162575, PMID 22370319, PMID 22480131, PMID 27020837, PMID 28916371, PMID 31753727, PMID 33160359, PMID 33989025, PMID 34795131, PMID 35388003, PMID 40256659, PMID 40591902

NIH funding

2014 (1), U10CA031946 (1), U10CA180821 (1)